Iron therapy: Clinical Trials

5 trials of Iron therapy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed. 4 Phase 3, 1 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 34Completed 4
Early Phase 11Completed 1

Follow Iron therapy: new trials by email Literature Review of Iron therapy trials Research Report on Iron therapy

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of Intravenous Iron Supplementation in Reducing Allogenic Blood Transfusion
Iron Isomaltoside 1000, placebo - Complications
Early Phase 1CompletedAin Shams University802019-09-202020-01-22
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)
Daprodustat (GSK1278863), Placebo, Iron therapy - Anaemia
Phase 3CompletedGlaxoSmithKline6142018-03-052024-04-02
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)
Daprodustat, Darbepoetin alfa, Iron therapy - Anaemia
Phase 3CompletedGlaxoSmithKline3122017-05-112021-10-20
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
Daprodustat, rhEPO, Placebo - Anaemia, Aspergillosis, Allergic Bronchopulmonary
Phase 3CompletedGlaxoSmithKline29642016-09-282021-12-03
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Daprodustat, Darbepoetin alfa, Placebo - Anaemia
Phase 3CompletedGlaxoSmithKline38722016-09-272024-04-02

Conditions studied

Anemia (4)  ·  Renal Insufficiency, Chronic (4)  ·  Aspergillosis, Allergic Bronchopulmonary (1)  ·  Kidney Failure, Chronic (1)

Sponsors

GlaxoSmithKline (4)  ·  Ain Shams University (1)

Countries

Argentina (4)  ·  Australia (4)  ·  Canada (4)  ·  Italy (4)  ·  Mexico (4)  ·  Poland (4)  ·  Russia (4)  ·  South Korea (4)  ·  Spain (4)  ·  United Kingdom (4)  ·  United States (4)  ·  Brazil (3)  ·  France (3)  ·  Germany (3)  ·  India (3)

Top investigators

Ayman Shoeb, professor (1)

Results publications

PMID 36005278, PMID 36565721, PMID 38383961, PMID 33744933, PMID 34739194, PMID 35377393, PMID 36739866

NIH funding

2016 (3), 2017 (1)